ACN Newswire

Hong Kong delegation concludes mission in Riyadh

31 10 月, 2025

HONG KONG, Oct 31, 2025 - (ACN Newswire via SeaPRwire.com) – A business delegation jointly organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC) and led by Financial Secretary Paul Chan visited Riyadh, the capital of Saudi Arabia, from 27 to 31 October.The delegation attended the Future Investment Initiative (FII) Summit and met with senior government officials and business leaders to promote collaboration between Hong Kong and Saudi Arabia in areas, such as innovation and technology (I&T), smart city, AI, fintech and biotechnology, supporting the goals of Saudi Arabia’s Vision 2030.The visit successfully fostered exchange between Hong Kong and Chinese Mainland companies based in Hong Kong and their Saudi counterparts, deepened their understanding of the Middle East market and promoted Hong Kong’s unique role as a superconnector and super value-adder in global trade.Saudi Arabia is the largest economy in the Middle East, with a GDP of US$ 1.084 trillion in 2024. As of 2024, it is Hong Kong’s fourth-largest trading partner and third-largest export market in the region. Despite its vast oil reserves, Saudi Arabia’s Vision 2030 aims to reduce reliance on oil and transform the country into a private sector-led, open economy. The plan seeks to enhance national competitiveness and attract foreign investment, particularly in infrastructure, tourism and green energy.Saudi Arabia’s economic transformation presents new opportunities for Hong Kong and mainland enterprises. The composition of the delegation reflects the strong interest of both business communities in the Saudi market and highlights Hong Kong’s role as a key platform connecting international and mainland enterprises. The delegation comprised around 40 representatives from sectors, including I&T, smart cities, AI, fintech and biotechnology.On 28 October, the delegation attended the FII Summit opening ceremony and a key thematic discussion session, at which Financial Secretary Paul Chan shared Hong Kong's experience in promoting various public-private partnership models. He noted that the HKSAR Government is expediting the development of the Northern Metropolis as a new engine for economic diversification, a key base for I&T industries and a source of quality employment opportunities.”In addition to attending the FII Summit, the delegation held meetings with local chambers and institutions, including Saudi Awwal Bank, Saudi National Bank, Riyadh Chamber of Commerce and Industry and Saudi Chinese Business Council. They also visited major development projects, including Diriyah Gate Development Authority, Red Sea Global, the New Murabba smart city and The Garage technology park. These engagements facilitated exchange in investment, cross-border finance, market expansion, academic collaboration and professional services.A highlight of the visit was the Hong Kong–Saudi Arabia Business Dinner, which provided a valuable platform for in-depth discussions between Saudi enterprises and the delegation. The event fostered diverse collaboration opportunities and led to the signing of multiple memoranda of understanding (MoU) and cooperation agreements, covering areas, such as smart mobility, green energy, AI, robotics and digital transformation, laying a solid foundation for future partnerships.Anna Cheung, Assistant Executive Director of the HKTDC, said: “The HKTDC is honoured to co-organise this mission with the HKSAR Government. Led by the Financial Secretary, this visit to Riyadh has helped Hong Kong and mainland enterprises based in the city explore new business opportunities and further strengthen Hong Kong-Saudi economic ties.”She added that the HKTDC will continue to promote bilateral cooperation through exhibitions, forums, overseas missions and business matching activities, and looks forward to seeing more Saudi enterprises leverage Hong Kong as a gateway to the Chinese Mainland and the wider Asian market.Multiple MoUs and cooperation agreements were signed at the Hong Kong-Saudi Arabia Business Dinner on 30 October:Hong Kong Trade Development Council and Digital Cooperation OrganizationBeijing Yunji Technology Co., Ltd and Young Life Travel and Tourism Co., LimitedI2Cool Company Limited and Madar Building Materials Company LimitedMaphive Technology Limited and Arabian Business Machines Company, a subsidiary of Olayan Saudi Holding CompanyShenzhen RabbitPre Intelligence Technology Co., Ltd and HIBOBI Technology LimitedPhoto Download: https://bit.ly/4opjihuAnna Cheung, Assistant Executive Director of the HKTDC (third left, front row), and members of the business delegation attended the FII Summit opening ceremony and a key thematic discussion session on 28 October, at which Financial Secretary Paul Chan (fourth left, front row) delivered remarksGroup photo of the delegation’s visit to the Saudi National BankThe delegation held a bilateral meeting with the Riyadh Chamber of Commerce and IndustryThe delegation met with representatives of Diriyah Gate Development AuthorityThe Hong Kong-Saudi Arabia Business Dinner was held in Riyadh on 30 October, providing a platform for in-depth exchange between local enterprises and delegation members to explore collaboration opportunities. The event led to the signing of several multiple memoranda of understanding (MoU) and cooperation agreementsMedia enquiriesHKTDC’s Communication & Public Affairs Department:Jane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgSam HoTel: (852) 2584 4569Email: sam.sy.ho@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

TruMerit 公司彼得·普雷佐西当选为联合国咨商地位非政府组织会议主席

31 10 月, 2025

纽约, 2025年10月31日 - (亚太商讯 via SeaPRwire.com) - TruMerit 公司总裁兼首席执行官彼得·普雷佐西（Peter Preziosi）当选为联合国咨商地位非政府组织会议（简称 CoNGO）主席。CoNGO | TruMerit联合国咨商地位非政府组织会议，亦称为 CoNGO，与 TruMeritCoNGO 是一个成立于 1948 年的国际非政府组织，其与联合国的关系基于联合国经济及社会理事会（ECOSOC）授予的“全面咨商地位”（General Consultative Status）。该组织目前拥有来自世界各地的 525 个会员组织以及 106 个准会员。普雷佐西博士（Dr. Preziosi）于本周在第 28 届 CoNGO 大会上当选为 2025—2029 任期主席。大会在纽约举行，同时也有来自全球各地的组织以线上方式参会。他接替了自 2017 年起担任 CoNGO 主席、并曾在 2007 至 2011 年间任职的联合卫理公会总会社会与公共事务委员会驻联合国首席代表利贝拉托·C·包蒂斯塔牧师博士（Rev. Dr. Liberato C. Bautista）。TruMerit 自 2018 年起成为 CoNGO 成员，并积极参与该组织事务，曾担任 CoNGO 理事会秘书以及会员委员会主席。普雷佐西博士（Dr. Preziosi）是首位担任 CoNGO 主席的注册护士。他是一位非营利机构高管，自 2023 年初起领导 TruMerit（前称 CGFNS International），这是一家致力于促进全球卫生工作者伦理流动与职业发展的卫生人力资源发展组织。此前，他曾就职于世界卫生组织（WHO），协助建立该机构的技术驱动型全球学习中心——世卫学院（WHO Academy）。前任主席包蒂斯塔牧师博士（Dr. Bautista）对普雷佐西博士的当选表示热烈祝贺。他说：“普雷佐西博士在 TruMerit 与世卫组织的工作经验，加上他对多边主义的深切奉献以及他在公民社会中的积极参与，为我们对 CoNGO 的未来带来了信心。在这个公民社会的声音与影响力对于塑造以人类尊严、人权及地球可持续性为核心的共同未来至关重要的时代，普雷佐西博士的领导力有望进一步强化 CoNGO 在联合国体系内外，推动民主与公平参与的重要作用。”普雷佐西表示：“长期以来，CoNGO 一直是非政府组织的重要汇聚平台，是连接公民社会与联合国之间的桥梁，也是包容性多边主义的坚定倡导者——这一理念遗憾地正日益受到冲击。”他进一步指出：“对此，我们应当坚持认为公民社会在联合国的参与不是一种请求，而是一项原则——这一原则对确保多边主义的合法性、有效性和伦理性至关重要，也因此对于实现可持续发展目标以及维护法治具有关键意义。”关于 CoNGO（联合国咨商地位非政府组织会议）联合国咨商地位非政府组织会议（Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations，简称 CoNGO）是一个独立的国际会员协会，成立于 1948 年——《世界人权宣言》发表的同一年。作为具有联合国经济及社会理事会（ECOSOC）全面咨商地位的非政府组织（NGO），CoNGO 的工作涉及整个联合国体系，包括秘书处、各专门机构、条约机构、区域委员会、研究所、峰会及世界会议。CoNGO 全心全意支持《联合国宪章》中所载的目标与价值观，并积极倡导通过多边主义来应对全球政治、环境、卫生及其他挑战。近 30 个隶属于 CoNGO 的实质委员会（即 NGO 委员会）在纽约、日内瓦、维也纳及世界各地区运作，体现了 CoNGO 对联合国体系使命的坚定支持。CoNGO 的成员涵盖广泛领域的非政府组织，这些组织不仅与联合国保持咨商关系，也彼此合作，并与志同道合的利益相关方携手共进。官方网站：ngocongo.org关于 TruMeritTruMerit 是全球领先的医疗人力发展机构。前身为 CGFNS International，该组织拥有近 50 年历史，致力于协助护理人员与其他医疗工作者——以及负责发照与聘用的机构——在寻求在美国及其他国家执业许可时，验证其教育背景、专业技能与实践经验，促进其职业流动性。作为 TruMerit，该机构的使命已扩展为建立符合全球快速变迁健康需求的人力资源能力。通过旗下的全球健康人力发展研究院（Global Health Workforce Development Institute），TruMerit 正在推动以实证为基础的研究、思想领导与倡议，支持各项医疗人力发展方案，包括全球认可的执业标准与认证，藉此强化医疗工作者的职业发展途径。联系信息David St. Johndstjohn@trumerit.org来源: TruMerit Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

The Executive Centre Unveils New Premium Flexible Workspace at One IFC, Central Hong Kong

31 10 月, 2025

- Expansive 20,000 square feet centre featuring nearly 300 workstations in the prestigious One IFC.- Luxurious VIP Lounge and designer Members’ Lounge complemented by a fully serviced Barista Bar.- TEC's 13th centre in Hong Kong, reinforcing its leadership in premium flexible workspace solutions.HONG KONG, Oct 31, 2025 - (ACN Newswire via SeaPRwire.com) – The Executive Centre (TEC), a premium flexible workspace provider, is proud to announce the grand opening of its latest centre at Level 9, One IFC, an iconic address in the heart of Central Hong Kong. This new centre spans nearly 20,000 square feet and accommodates close to 300 workstations, marking a significant milestone as TEC’s 13th centre in the city.This new location epitomizes exclusivity and sophistication, offering a range of high-end amenities tailored to meet the diverse needs of modern professionals. Among its offerings are premium Private Offices, Manager Suites, and an exclusive luxury VIP Lounge designed for high-level meetings, complemented by two additional Meeting Rooms equipped with cutting-edge technology to facilitate seamless collaboration.Jennifer So, City Head of Hong Kong at The Executive Centre, remarked on the importance of this launch: “Since our inception in Hong Kong in 1994, we have strived to set the standard for premium flexible workspaces across Asia. Today, as we celebrate the opening of our new centre at One IFC during our 31st anniversary, we reaffirm our unwavering commitment to excellence. This centre is not merely a new location; it embodies our belief that a harmonious blend of luxury and flexibility is essential for providing our clients with a competitive edge in an ever-evolving business landscape. Our expansion here reflects our confidence in the Hong Kong market and our commitment to supporting businesses in this vibrant city.”The centre features a meticulously designed Members’ Lounge that boasts breathtaking panoramic views of Victoria Harbour, along with a fully serviced Barista Bar. The interior design, characterized by curve-inspired ceilings, a contemporary marble reception, and warm wooden accents, creates an inviting and inspiring atmosphere for all members.Additional highlights include:- A luxurious VIP Lounge that exudes a sense of ‘quiet luxury’ with designer furnishings and exquisite finishes.- Two contemporary Meeting Rooms equipped with cutting-edge technology and exceptional soundproofing for privacy and focus.- Over 2,000 square feet of elegantly appointed Event Space, ideal for hosting corporate events and networking functions.- A thoughtfully designed nursing room featuring a massage chair, catering to the needs of working parents.The Executive Centre at One IFC stands as a testament to TEC’s dedication to delivering best-in-class service and innovative workspace solutions, ensuring that members have access to an environment that fosters productivity and creativity.As TEC continues to expand its footprint in Hong Kong, the opening of this new centre at One IFC reinforces its position as a pioneer in the flexible workspace sector, committed to enhancing the professional experience for all its members.About The Executive CentreThe Executive Centre (TEC) is a premium flexible workspace provider, opened its doors in Hong Kong in 1994 and has over 240+ Centres in 37 cities and 15 markets.The Executive Centre caters to professionals and industry leaders. TEC has a global network spanning Greater China, Southeast Asia, North Asia, India, Sri Lanka, the Middle East, and Australia. Each Executive Centre offers a prestigious address with the advanced infrastructure to meet the needs of its Members.Privately owned and headquartered in Hong Kong, TEC provides Private and Shared Workspaces, Business Services, and Meeting & Events facilities to suit its clients’ business' needs.www.executivecentre.comPress EnquiriesThe Executive CentrePebble LeePebble_lee@executivecentre.com / +852 3951 9888 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

Doubleview Gold Corp Announces Non-Brokered Private Placement of Flow-Through Shares at $1.00 per share along with Non-Flow-Through Units

31 10 月, 2025

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - October 30, 2025) - Doubleview Gold Corp. (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) (the "Company" or "Doubleview") is pleased to announce a non-brokered private placement of flow-through shares and non-flow-through units for gross proceeds of up to C$10,000,000 (the "Private Placement"). Proceeds of the Private Placement shall be used to fund the current exploration program and general working capital. Proceeds of the sale of the FT Shares will be used for exploration work on its BC projects, particularly for the polymetallic Hat Project, located in northwestern BC. This work includes drilling, geological advisory and analytical services as well as other development work and other "Canadian exploration expenses" that qualify as "flow-through mining expenditures" (as such terms are defined in the Income Tax Act (Canada) (the "Tax Act")).The flow-through portion of the Private Placement will consist of up to 5,000,000 flow-through Shares ("FT shares ") at a price of $1.00 per FT share for up to C$5,000,000.Additionally, the Company will issue up to 7,142,857 hard dollar units ("non-FT Units") at a price of $0.70 per non-FT Unit, for up to C$5,000,000. Each non-FT Unit will consist of one common share and one full Warrant at an exercise price of $1.00 for 24 months from the date of issue. Each Warrant shall be subject to an accelerated expiry date at the option of the Company in the event the ten (10) day volume-weighted average price of the common shares of the Company on the TSXV for any ten (10) consecutive trading days is $1.25 or more.Pursuant to applicable Canadian securities laws and in accordance with the TSX Venture Exchange policies, all securities issued under this Offering will be subject to applicable resale restrictions under applicable securities laws and to the Exchange hold period of four-months and one day from the date of issuance. In connection with the Private placement, Doubleview may pay a finder's fees in accordance with the policies of the TSXV consisting of cash and/or finder's shares.The closing of the Offering is subject to receipt of all necessary regulatory approvals including the TSX Venture ExchangeAbout Doubleview Gold CorpA mineral resource exploration and development company is headquartered in Vancouver, British Columbia, Canada. It is publicly traded on the TSX Venture Exchange (TSXV: DBG) (OTCQB: DBLVF) (WKN: A1W038) and (FSE: 1D4). Doubleview focuses on identifying, acquiring, and financing precious and base metal exploration projects across North America, with a strong emphasis on British Columbia. The company enhances shareholder value through the acquisition and exploration of high-quality gold, copper, cobalt, scandium, and silver projects-collectively critical minerals-utilizing cutting-edge exploration techniques.Doubleview's success is deeply rooted in the unwavering support of its long-term shareholders, supporters, and institutional investors. Their ongoing commitment has been instrumental in advancing the company's strategic initiatives. Doubleview looks forward to further collaborative growth and development and continues to welcome active participation from its valued stakeholders as the company expands its portfolio and strengthens its position in the critical minerals sector.About the Hat Polymetallic DepositThe Hat Deposit, located in northwestern British Columbia, is a polymetallic porphyry project with major resources of copper, gold, cobalt, and the potential for scandium. As one of the region's significant sources of critical minerals, the Hat deposit has undergone targeted exploration and development. The 0.2% CuEq cut-off resource estimate, as of the recently completed Mineral Resource Estimate and the Company's July 25, 2024, news release, is summarized below:Open Pit Model HatResource CategoryTonnageAverage GradeMetal ContentCuEqCuCoAuAgCuEqCuCoAuAgMt%%%g/tg/tmillion lbmillion lbmillion lbthousand ozthousand ozIn PitIndicated1500.4080.2210.0080.190.421,353733289292,045Inferred4770.3440.1850.0090.150.493,6191,945912,3287,575 Scandium potential for the Hat Deposit is estimated to be 300 to 500 million tonnes at an average grade of 40 ppm (0.004%) Sc2O3.For further details, please refer to the Company's July 25, 2024 news release.Qualified Person:Erik Ostensoe, P. Geo., a consulting geologist, and Doubleview's Qualified Person with respect to the Hat Project as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects, has reviewed, and approved the written technical disclosure contained in the news release. He is not independent of Doubleview as he is a shareholder in the company.On behalf of the Board of Directors,Farshad Shirvani, President & Chief Executive OfficerFor further information please contact:Doubleview Gold CorpVancouver, BC Farshad ShirvaniPresident & CEOT: (604) 678-9587E: corporate@doubleview.caNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.The information contained herein contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation (collectively, "forward-looking statements"). Forward-looking statements relate to information that is based on assumptions of management, forecasts of future results, and estimates of amounts not yet determinable. All statements, other than statements of historical fact, are forward-looking statements and are based on predictions, expectations, beliefs, plans, projections, objectives and assumptions made as of the date of this news release, including without limitation: the size of the Private Placement and other statements concerning the Private Placement; the anticipated use of proceeds from the Private Placement; the renunciation to the purchasers of FT Shares and timing thereof; the tax treatment of the FT Shares and the Company's plans regarding exploring its mineral exploration properties; anticipated results of geophysical drilling programs, geological interpretations and potential mineral recovery. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ from those reflected in the forward-looking statements, including, without limitation: risks related to failure to obtain adequate funding on a timely basis and on acceptable terms; risks related to the outcome of legal proceedings; political and regulatory risks associated with mining and exploration; risks related to the maintenance of stock exchange listings; risks related to environmental regulation and liability; the potential for delays in exploration or development activities or the completion of feasibility studies; the uncertainty of profitability; risks and uncertainties relating to the interpretation of drill results, the geology, grade and continuity of mineral deposits; risks related to the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; results of prefeasibility and feasibility studies, and the possibility that future exploration, development or mining results will not be consistent with the Company's expectations; risks related to the gold price and other commodity price fluctuations; and other risks and uncertainties related to the Company's prospects, properties and business detailed elsewhere in the Company's disclosure record. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements. Investors are cautioned against attributing undue certainty or reliance on forward-looking statements. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise any forward-looking statements, other than as required by applicable law, to reflect new information, events or circumstances, or changes in management's estimates, projections or opinions. Actual events or results could differ materially from those anticipated in the forward-looking statements or from the Company's expectations or projections.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272690 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus

31 10 月, 2025

HONG KONG, Oct 31, 2025 - (ACN Newswire via SeaPRwire.com) – HighTide Therapeutics, Inc. (2511.HK), a biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic metabolic diseases, announced positive 52-week safety and efficacy results from the open-label extension (OLE) phases of two Phase III trials (SYMPHONY-1 and SYMPHONY-2) evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM).The 52-week data from these two Phase III clinical trials demonstrate the durability of response and highlight the comprehensive long-term clinical benefits of HTD1801 in patients with T2DM. HighTide plans to submit a new drug application (NDA) for HTD1801 as a treatment for T2DM to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) later this year.SYMPHONY-1 (NCT06350890) and SYMPHONY-2 (NCT06353347) are randomized, double-blind, placebo-controlled, Phase III clinical trials designed to evaluate the efficacy and safety of HTD1801 in adults with T2DM and inadequate glycemic control despite diet and exercise (SYMPHONY-1; N=408) or with Metformin (SYMPHONY-2; N=551). The primary endpoint in both studies was the change in glycated hemoglobin (HbA1c) from baseline with HTD1801 compared to placebo after 24 weeks of treatment. Patients were eligible to continue in a 28-week OLE during which all patients received HTD1801; Durability of response across efficacy endpoints was evaluated based on the change from baseline to Week 52.Efficacy observed during the 24-week double-blind period was durable and maintained with longer-term treatment through 52 weeks in both studiesSYMPHONY-1 (HTD1801 as monotherapy): At week 24, the reduction from baseline in HbA1c with HTD1801 (-1.3%) was superior to placebo. HbA1c reductions were maintained in patients who continued receiving HTD1801 (-1.2% at Week 52). Placebo patients who switched to HTD1801 saw a reduction in HbA1c of -1.3% at Week 52, substantiating the double-blind phase findings.SYMPHONY-2 (HTD1801 as an add-on therapy to Metformin): At week 24, the reduction from baseline in HbA1c with HTD1801 (-1.2%) was superior to placebo. HbA1c reductions were sustained in patients who continued receiving HTD1801 (-1.1% at Week 52). Placebo patients who switched to HTD1801 saw a reduction in HbA1c of -1.2% at Week 52, also substantiating the double-blind phase findings.In both studies, the durability of effect on other cardiometabolic and renal endpoints was maintained at 52 weeks, suggesting comprehensive advantages of HTD1801 beyond glycemic control with long-term treatment.In both studies, the proportion of patients receiving HTD1801 during the double-blind phase who achieved target HbA1c<7.0% was sustained through Week 52. The lipid-lowering effects observed during the double-blind phase, including significant reductions in low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C), were also maintained. Long-term HTD1801 treatment also led to continued reductions in key inflammatory biomarkers, including gamma-glutamyl transferase (GGT) and high-sensitivity C-reactive protein (hs-CRP), both associated with cardiovascular risk in patients with T2DM.Notably, while estimated glomerular filtration rate (eGFR) remained stable in the overall population, the improvement of eGFR in patients with mild renal impairment at Week 24 was preserved at Week 52. These data highlighting the potential renal benefit of HTD1801 will be presented at a forthcoming scientific meeting.Favorable safety and tolerability profileOverall, long-term safety and tolerability were favorable and consistent with the double-blind phase. The types and severity of AEs did not increase with continued HTD1801 treatment compared to newly initiated HTD1801 treatment.“The robust 52-week results from these trials reinforce that HTD1801 may represent a novel and truly differentiated therapeutic option for patients with T2DM,” said Dr. Linong Ji, Lead Principal Investigator, former Vice President of the International Diabetes Federation (IDF), and Director of the Peking University Diabetes Center and the Department of Endocrinology and Metabolism at Peking University People’s Hospital. “As a first-in-class new molecular entity, HTD1801 is an anti-inflammatory metabolic modulator (AIMM) with a dual mechanism of action, AMP kinase activation and NLRP3 inflammasome inhibition, distinct from existing therapies. Its unique profile is designed not only to lower blood glucose, but also to improve lipid metabolism, exert anti-inflammatory effects, and potentially enhance renal function, supporting its potential as a backbone therapy to address the cardiovascular-kidney-metabolic (CKM) syndrome by targeting the underlying drivers of diabetes and diabetes-related complications. In addition, the unique mechanism allows for potential of combination treatments”“We extend our deepest gratitude to the patients who participated in these pivotal studies,” said Dr. Liping Liu, Founder, Chairperson, and CEO of HighTide Therapeutics. “Given the progressive nature of T2DM, durability of effect is a key determinant of long-term therapeutic success. The sustained beneficial effects of HTD1801 on metabolic, inflammatory, and renal parameters help reduce the risk of both microvascular and macrovascular complications. We look forward to sharing results from our Phase III head-to-head study with dapagliflozin, and will continue to explore HTD1801’s potential to deliver patients with chronic metabolic diseases a truly comprehensive, long-term treatment solution.”About Type 2 Diabetes Mellitus (T2DM)According to the International Diabetes Federation (IDF), 589 million adults (ages 20-79) were living with diabetes in 2024, and this number is projected to grow to 853 million (representing 1 in 8 adults) by 2050, of these, around 90% are T2DM cases. China has the largest population of diabetes patients worldwide, estimated to be 148 million in 2024, and projected to grow to 168 million in 2050. Diabetes is a global societal burden leading to over 6 million deaths per year. To address this urgent challenge, there is a critical need for innovative therapies that can deliver comprehensive clinical benefits for patients worldwide.About HTD1801HTD1801 is a first-in-class new molecular entity that targets the residual risks underlying cardiovascular–kidney–metabolic (CKM) diseases. It is an orally delivered, anti-inflammatory metabolic modulator (AIMM) that, as a single molecule, exerts a unique dual mechanism of action through activation of AMP Kinase and inhibition of the NLRP3 inflammasome, two complementary pathways that mitigate metabolic dysfunction. Multiple global clinical studies have demonstrated the comprehensive benefits of HTD1801, including improved insulin sensitivity, glycemic control, lipid lowering, renal protection, weight reduction, hepatic improvement, and anti-inflammatory effects. Collectively, these findings support the potential of HTD1801 to serve as a foundation therapy in CKM disease management. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

全球首创抗炎代谢调节剂HTD1801完成2型糖尿病III期临床研究 展现持续52周的综合获益与安全性优势

31 10 月, 2025

香港, 2025年10月31日 - (亚太商訊) - 君圣泰医药（股票代码: 2511.HK），一家专注于开发多功能创新疗法，以解决代谢性慢病未满足临床需求的创新药公司，宣布HTD1801在2型糖尿病（T2DM）患者中开展的两项III期临床试验（SYMPHONY-1和SYMPHONY-2）已顺利完成。在包含双盲治疗期和开放延长治疗期（OLE）的52周研究中，HTD1801展现出长期持久的疗效与良好的安全性。两项III期临床研究的52周数据充分验证了HTD1801疗效的持久性，并进一步凸显其为T2DM患者带来的长期综合临床获益。君圣泰医药计划于今年内向国家药品监督管理局（NMPA）药品审评中心（CDE）递交HTD1801治疗T2DM适应症的新药上市申请（NDA）。SYMPHONY-1（NCT06350890）及SYMPHONY-2（NCT06353347）试验是两项随机、双盲、安慰剂对照的III期临床试验，旨在分别评估HTD1801在饮食及运动干预后血糖控制不佳（SYMPHONY-1; N=408）和二甲双胍治疗后血糖控制不佳（SYMPHONY-2; N=551）的T2DM成人受试者中的有效性和安全性。两项研究的主要疗效终点为：与安慰剂相比，HTD1801治疗24周后糖化血红蛋白（HbA1c）相对于基线的变化。随后所有受试者进入为期28周的OLE期并接受HTD1801的治疗。研究继续评估了各疗效终点在第52周时相对于基线变化，以进一步验证HTD1801疗效的持久性。降糖疗效稳健持久：24 周双盲期疗效得到长期维持，52 周数据印证 HTD1801 带来持久获益SYMPHONY-1（单药治疗）：HTD1801治疗组第24周HbA1c较基线平均变化值为-1.3%，显著优于安慰剂组。持续接受HTD1801治疗的患者在第52周时HbA1c的较基线降幅（-1.2%）维持稳定。由安慰剂转至HTD1801治疗的患者，在第52周时其HbA1c较基线的平均变化值为-1.3%，进一步验证了双盲期结果的可靠性。SYMPHONY-2（与二甲双胍联合治疗）：HTD1801治疗组第24周HbA1c较基线平均变化值为-1.2%，显著优于安慰剂组。持续接受HTD1801治疗的患者在第52周时HbA1c的较基线降幅（-1.1%）依然稳定。由安慰剂转换至 HTD1801治疗的患者，在第52周时其 HbA1c较基线的平均变化值为-1.2%，再次印证了双盲期的研究结果。心肾代谢多重获益：HTD1801 对多项心肾代谢指标的改善在 52 周时均持续获益两项研究中，双盲期HbA1c达标（HbA1c <7.0%）的患者比例在第 52 周时仍保持稳定。与此同时，HTD1801 在降低血脂方面的疗效亦长期稳定，包括低密度脂蛋白胆固醇（LDL-C）与非高密度脂蛋白胆固醇（non-HDL-C）均显著下降。HTD1801长期治疗还可持续降低与心血管事件及T2DM患者临床结局密切相关的炎症标记物γ-谷氨酰转移酶（GGT）和超敏C反应蛋白（hs-CRP）。值得关注的是，全体患者的估算肾小球滤过率（eGFR）在治疗期间保持稳定。在合并轻度肾功能损害的患者中，第 24 周观察到的 eGFR 改善在第 52 周时仍然保持，显示HTD1801的肾脏保护潜力。相关数据将在近期学术会议公布。良好的安全性与耐受性HTD1801 在长期治疗中展现出良好的安全性与耐受性，与双盲期结果保持一致。对于接受 HTD1801 治疗的患者，治疗期延长不会增加其不良事件的类型与严重程度。该临床试验的主要研究者，前国际糖尿病联盟（IDF）副主席、北京大学糖尿病中心主任、北京大学人民医院内分泌和代谢科主任纪立农教授指出：“这两项临床试验52 周研究结果进一步表明，HTD1801有望成为T2DM患者差异化的创新治疗选择。HTD1801是全球首创的新分子实体，作为抗炎代谢调节剂（AIMM），具有激活AMPK并抑制 NLRP3 炎性小体的双重作用机制，与现有治疗方案在机制上有很大的差异。其独特药理机制在临床疗效上表现出多重获益：不仅能够有效降糖，还可改善脂质代谢，抑制慢性代谢性炎症，并有改善肾功能的潜力。这一综合疗效使 HTD1801 有潜力成为心肾代谢系统疾病（CKM）的新治疗药物，有改善糖尿病及相关并发症的关键驱动因素的潜力，并和现有降糖药物机制互补，能够联合使用。”君圣泰医药的创始人、董事长兼首席执行官刘利平博士表示：“我们向参与这几项关键临床研究的患者致以诚挚的谢意。对于T2DM 这类慢性进展性疾病而言，疗效的持久性是衡量长期治疗成功的核心标准。HTD1801在代谢、炎症及肾功能等多个层面展现出的持久获益，有助于降低微血管及大血管并发症的风险。我们期待即将公布的与达格列净头对头的III期研究结果，并将继续挖掘 HTD1801 其它适应症的临床潜力，为慢性代谢性疾病患者提供更综合全面、且长期有效的治疗方案。”关于2型糖尿病（T2DM）根据国际糖尿病联盟（IDF）统计，2024年有5.89亿成年人（20-79岁）患有糖尿病，预计到2050年将增至8.53亿（即每8个成年人中就有1人患有糖尿病），其中90%为T2DM。中国是全球糖尿病患者人数最多的国家，2024年患者人数约为1.48亿人，预计2050年将增至1.68亿人。目前，糖尿病每年导致超过600万人死亡，该疾病及其相关的一系列代谢问题，给社会和人民带来了沉重的负担。为应对这一急迫挑战，临床上急需为全球患者带来综合获益的创新疗法。关于HTD1801HTD1801是一款全球首创的新分子实体，旨在解决心肾代谢系统疾病（CKM）的未满足临床需求。HTD1801是口服抗炎及代谢调节剂（AIMM），作为单一分子具有独特双机制 ，通过激活AMPK及抑制NLRP3炎症小体发挥其生物学活性；这种互补协同的双机制作用可有效缓解代谢问题。全球多项临床结果验证HTD1801具有“一药多效”的特性，能够为患者带来综合获益，包括改善胰岛素敏感性、血糖控制、血脂降低、肾脏保护、体重减轻、肝脏获益及抗炎等。基于此，HTD1801有潜力成为CKM领域的基础性治疗药物。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com